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The introduction of the calcineurin inhibitors (CNIs) cyclosporine and tacrolimus greatly reduced the 
rate of allograft rejection, although their chronic use is marred by a range of side effects, among them 
vascular toxicity. In transplant patients, it is proved that innate immunity promotes vascular injury 
triggered by ischemia-reperfusion damage, atherosclerosis and hypertension. We hypothesized that 
activation of the innate immunity and inflammation may contribute to CNI toxicity, therefore we 
investigated whether TLR4 mediates toxic responses of CNIs in the vasculature. Cyclosporine and 
tacrolimus increased the production of proinflammatory cytokines and endothelial activation markers 
in cultured murine endothelial and vascular smooth muscle cells as well as in ex vivo cultures of murine 
aortas. CNI-induced proinflammatory events were prevented by pharmacological inhibition of TLR4. 
Moreover, CNIs were unable to induce inflammation and endothelial activation in aortas from TLR4−/− 
mice. CNI-induced cytokine and adhesion molecules synthesis in endothelial cells occurred even in the 
absence of calcineurin, although its expression was required for maximal effect through upregulation 
of TLR4 signaling. CNI-induced TLR4 activity increased O2−/ROS production and NF-κB-regulated 
synthesis of proinflammatory factors in cultured as well as aortic endothelial and VSMCs. These data 
provide new insight into the mechanisms associated with CNI vascular inflammation.
Chronic allograft vasculopathy is a pathological condition that impairs endothelial function and integrity and 
negatively impacts on the half-life of both solid organ engrafted and patients. Among many other causes that 
contribute to chronic allograft vasculopathy, such as immune rejection, ischemic damage, hypertension and ath-
erosclerosis, it is widely known that therapies based on the use of the calcineurin inhibitors (CNIs) cyclosporine 
A (CsA) and tacrolimus are main contributors in the development of this transplant-associated complication1–4.
Endothelial damage and dysfunction that results in systemic hypertension are among the most recognized 
vascular affections in solid organ transplantation patients on CNIs. Mechanistically, apoptosis, oxidative stress 
and the inhibition of endothelium-derived NO production may contribute to CNI-induced endothelial cell dam-
age and dysfunction5–7 . Moreover, there are evidences that vascular toxicity of CNIs also implicates vascular 
smooth muscle cells (VSMCs)8. Moreover, higher expression levels of TGFβ -1 receptor in endothelial cells caused 
renal arteriolar hyalinosis, which is associated to kidney dysfunction and glomerulosclerosis9. Even though CNIs 
potently reduce the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κ B) in 
T cells, we have demonstrated the opposite effect in renal tubular cells10. Nonetheless, whether a similar NF-κ B 
activation leading to inflammation can occur in vascular cells exposed to CNIs has not been addressed yet.
Activation of the innate immune system resulting in inflammation is an adaptive response aiming at elimi-
nating invading microorganisms or re-establishing normal tissue functions after damage11. However, sustained 
stimulation of the innate immunity may lead to inflammatory diseases. Toll-like receptors (TLRs) are key sensors 
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of the innate immune system which are widely distributed in immune cells as well as in other cell types, including 
endothelial and VSMCs. Activation of TLRs results from binding to microbial toxins or pathogen-associated 
molecular patterns (PAMPs) and to intracellular ligands or damaged-associated molecular patterns (DAMPs) 
released from stressed tissues. Signaling through TLR4 requires engagement of the cytoplasmic adaptor mole-
cules Myeloid differentiation factor 88 (MyD88) and Toll/IL-1 receptor (TIR) domain-containing adaptor pro-
tein inducing interferon-β (IFNβ) (TRIF). Main downstream targets of MyD88 and TRIF-adapted signaling 
are the NF-κ B pathway, the MAPK cascades and the interferon pathway which is exclusively regulated from 
TRIF-derived signals12. A common end outcome in cell expressing TLR4 is the synthesis of many proinflam-
matory molecules, namely cytokines, chemokines and soluble mediators of inflammation13. On the other hand, 
TLR signaling must be restrained to avoid damaging and improper inflammatory responses through a battery of 
soluble decoy TLRs and intracellular negative regulators for TLR4-derived signaling pathways14. TLR4 expressed 
on endothelial and VSMCs has been proposed to contribute to vascular inflammatory responses15,16. TLR4 is also 
required for triggering early vascular events accessory to inflammation, such as endothelial activation during 
ischemic damage in acute kidney injury and allogenic kidney transplantation18,19. Moreover, recent investigations 
have highlighted a role of TLR4 in experimental vascular injury by mediating not only inflammation but also 
dysfunction, remodelling and stiffness associated with spontaneous or induced hypertension in rats20. These data 
pointed to a role of TLR4 activation in vascular damage and dysfunction. Nonetheless, the involvement of TLR4 
as mediator of CNI-induced vascular injury has not been studied to date. We show in this study that in relevant 
vascular cell types and in aortic tissue, CNIs induce vascular inflammation through a previously non described 
mechanism involving TLR4 activation.
Material and Methods
Cells and reagents. The murine MS1 (Mile Sven 1) pancreatic islet endothelial cell line, obtained from 
American Type Culture Collection (ATCC® , CRL-2279TM), is a commonly used model of microvascular endothe-
lium. MS1 cells were cultured in high glucose (4.5 g/l) Dulbecco’s modified Eagle’s medium (DMEM), supple-
mented with 5% decomplemented (heat inactivated) fetal bovine serum (FBS), 120 U/mL streptomycin/penicillin 
and 4 mM L-Glutamine, in 5% CO2 at 37 °C. MOVAS (ATCC® , CRL-2797TM) is an established VSMC line from 
C57BL/6 mice. Cells were grown in DMEM supplemented with 10% FBS, 2 mM L-Glutamine and 0.2 mg/ml 
G-418 (all reagents obtained from Lonza). For experiments, cells at 80% confluence were growth-arrested by 
serum starvation for 24 h. Endotoxin-free CsA (Calbiochem, Merck Chemicals) and tacrolimus (USBiological) 
stock solutions (10 mg/ml) were dissolved in ethanol. CLI-095 (InvivoGen) was used according to manufactur-
er’s time and dose recommendations. The NF-κ B inhibitor parthenolide, the TRIF inhibitor resveratrol and the 
antioxidants 4′-hydroxy-3′methoxyacetophenone (apocynin) and diphenyleneiodonium chloride (DPI) were 
from Sigma-Aldrich. These reagents were used at concentration derived from prior dose-response studies in our 
laboratory or from bibliographic data.
Gene expression studies. One μ g RNA isolated by Tripure (Roche) was reverse transcribed with High 
Capacity cDNA Archive Kit and real-time PCR was performed on a ABI Prism 7500 PCR system (Applied 
Biosystems, Thermo Fisher Scientific) using the DeltaDelta Ct method. RT-PCR was performed using the follow-
ing fluorogenic (FAM or VIC) predesigned primers (Applied Biosystems, Thermo Fisher Scientific): Ccl2/MCP1 
(Mm00441242_m1), Ccl5/RANTES (Mm01302428_m1), Il6 (Mm00446190_m1), Tnfa (Mm00443258_m1), 
Icam1 (Mm00516023_m1), Vcam1 (Mm01320970_m1), Sele (Mm01310197_m1), Et1 (Mm00438656_m1), Infb1 
(Mm00439552_s1), IRF1 (Mm01288580_m1), IRF7 (Mm00516793_m1). Results were expressed in copy num-
bers, calculated relative to unstimulated cells or aortas, after normalization against GAPDH using the ABIPrism 
7500 Fast sequence detection PCR system software (Applied Biosystems).
ELISA. Cells were stimulated with CsA (10 μ g/ml) or tacrolimus (20 μ g/ml) and murine MCP-1 and VCAM-1 
were determined in the supernatants by ELISA according to manufacturer’s recommendations (BD).
Gene silencing. Gene silencing by RNA interference in cultured cells was performed using predesigned 
small interfering RNA (siRNA) corresponding to MyD88 (#S201719), calcineurin (#S72075) or a scrambled siR-
NAs (#4390843) (Ambion, Thermo Fisher Scientific). Subconfluent cells were overnight transfected with 25 nM 
(MyD88), 100 nM (calcineurin) siRNA or with the scrambled siRNA used at the same concentration as the spe-
cific siRNA, employing 50 nM Lipofectamine RNAiMAX (Invitrogen) or treated only with lipofectamine vehicle, 
according to the manufacturer’s instructions. Then, cells were incubated with 10% heat-inactivated (FBS) for 24 h, 
followed by 24 h in serum-free medium before the experiments.
Western blot. Protein content from cell extracts homogenized in lysis buffer (50 mmol/L Tris, 150 mmol/L 
NaCl, 2 mmol/L EDTA, 2 mmol/L EGTA, 0.2% Triton X-100, 0.3% NP-40, 0.1 mmol/L PMSF, 25 mmol/L NaF) 
was determined by the bicinchoninic acid method (Pierce Biotechnology). Proteins were separated by 10% 
SDS-PAGE under reducing conditions and then blotted onto nitrocellulose membranes. Membranes were 
blocked with 5% skim milk in TBS-T (0.05 mol/L Tris, 0.15 mol/L NaCl, 0.05% Tween 20, pH 7.4). Thereafter, 
membranes were overnight probed at 4 °C with specific primary antibodies in the same blocking solution or 
5% BSA in TBS-T and then incubated with secondary HRP-conjugated antibodies for 1 h at room tempera-
ture. Primary antibodies used were: MyD88 (#4283), phospho-Iκ Bα (#2859) and phospho-p65 (Ser536) (#3033) 
from Cell Signaling Technology; calcineurin (panA) (#07-1491) from Merck Millipore and phospho-IRF3 
(pSer936) (#SAB4504031) from Sigma-Aldrich. Antibodies to α -Tubulin (Sigma-Aldrich) and mouse polyclonal 
anti-GAPDH (Merck-Millipore) were used to correct minor differences in protein loading.
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Immunofluorescence. MS1 cells seeded in 24-well culture plates over glass coverslips. Then, cells were fixed 
in 4% paraformaldehyde/PBS, permeabilized in 0.1% Triton X-100/ BSA 2%/ PBS for 5 minutes, washed with 
PBS and then blocked with 2% BSA/PBS for 1 h. Then, cells were incubated with rabbit polyclonal anti-RelA/p65 
(1:100) (Santa Cruz Biotechnology #sc-372) followed byAlexaFluorTM488 conjugated anti-rabbit antibody (1:500, 
Invitrogen) and nuclei counterstained with DAPI.
Tissue immunofluorescence was carried out in 5 μ m thick Tissue Tek OCT-embedded (Sakura Fineted 
Europe BV) aorta sections. Slides were rehydrated with 2% BSA in PBS during 1 h. After a blocking step, tis-
sue sections were overnight incubated with the following primaries antibodies: anti NF-κ B/p65 (1:50) (Santa 
Cruz Biotechnology #sc-372), anti CD31 (1:50) (Santa Cruz Biotechnology #sc-1506) and anti α SMA-FITC 
(1:300) (Sigma-Aldrich #F3777). Tissue incubation with p65 plus CD31 or α SMA antibodies was simultane-
ously carried out. After primary antibody step, tissue samples were incubated with the following secondary 
antibodies: AlexaFluorTM568 conjugated goat anti-rabbit antibody for detection of p65 in endothelial cells 
(1:250, Invitrogen), AlexaFluorTM647 conjugated goat anti-rabbit antibody for detection of p65 in VSMC (1:250, 
Invitrogen) and AlexaFluorTM488 donkey anti goat for CD31 (1:250, Invitrogen). Nuclei were counterstained with 
DAPI (Sigma-Aldrich).
In situ production of O2−/ROS was evaluated through the oxidative fluorescent dye dihydroethidium (DHE) 
(Molecular Probes, Thermo Fisher Scientific). Briefly, OCT-embedded aortic section were equilibrated in KHS 
(30 min, 37 °C) and incubated with DHE (5 μ M, 30 min, 37 °C). DHE was detected by excitation at 540 nm and 
emission at 610 nm. The elastin layer was captured by autofluorescence (excitation at 488 nm). Both cells and 
tissue section were mounted in ProLong® Gold Antifade Reagent (Invitrogen) and analyzed with a TCS SP5 
fluorescent laser scanning confocal microscope (Leica).
Tissue preparation. Studies were performed in 16–24 weeks old wild-type C57BL/6 mice (Charles River 
Laboratories) or in TLR4 knockout mice of the same background (kindly provided by Dr. Consuelo Guerri, 
Centro de Investigación Príncipe Felipe, Spain and originally donated by Dr. S. Akira, Osaka University, Japan). 
Animals were maintained at the local animal facilities, with free access to food and water, normal light-dark cycles 
and under special pathogen-free conditions. Mice were sacrificed under anesthesia with Isofluorane (Abbott 
Laboratories) and aortas were dissected free of fat and connective tissue. Then, tissue sections were placed in 
culture plates, covered with DMEM medium and left untreated overnight at 37 °C to recover the basal state. Next, 
aortic segments were stimulated with CsA or tacrolimus alone or in the presence of CLI-095, and then processed 
according to the procedure of interest. For assessment of O2−/ROS production and NF-κ B/p65 location by confo-
cal microscopy, tissue samples were placed in cold Krebs-Henseleit solution (KHS in mM: 115 NaCl, 25 NaHCO3, 
4.7 KCl, 1.2 MgSO4.7H2O, 2.5 CaCl2, 1.2 KH2PO4, 11.1 glucose, and 0.01 Na2EDTA) containing 30% sucrose 
for 20 min, then transferred to a cryomold containing a Tissue Tek OCT-embedding medium (Sakura Finetek 
Europe BV) and then frozen at − 80 °C. For gene expression studies, aorta segments were immediately frozen in 
liquid nitrogen and kept at − 80 °C. All the procedures on animals were performed according to the European 
Community and Animal Research Ethical Committee guidelines. The animal protocols were approved by the 
Instituto de Investigación Sanitaria Fundación Jiménez Díaz Animal Research Ethical Committee (body author-
ized by the Dirección General de Medioambiente, Consejería de medioambiente y Ordenación del Territorio, 
Comunidad de Madrid, RD 53/2013).
Statistics. Statistical analysis was performed using SPSS 11.0 (SPSS, Chicago, IL). Results are expressed as 
mean ± SEM. Significance at the p < 0.05 level was assessed by non-parametric Mann-Whitney test for two inde-
pendent samples.
Results
In murine endothelial cells, CNIs promote the synthesis of NF-κB-dependent chemokines and 
adhesion proteins. Endothelia are highly exposed to the toxic action of circulating CNIs. To assess whether 
CNIs induce direct proinflammatory effects in endothelial cells, cultured murine endothelial cells were treated 
with CsA or tacrolimus under standard in vitro dose and time conditions10,21 and the mRNA and protein expres-
sion of key proinflammatory cytokines and adhesion molecules were assessed by PCR and ELISA assays, respec-
tively. Treatment with CsA and tacrolimus caused a dose-dependent upregulation of the chemokines monocyte 
chemotactic protein-1/chemokine (C-C motif) ligand 2 (MCP1/CCL2) and regulated on activation normal T cell 
expressed and secreted/chemokine (C-C motif) ligand 5 (RANTES/CCL5) gene expression at 6 h (Fig. 1A). At the 
same time, CsA and tacrolimus also induced the mRNA synthesis of relevant vascular proinflammatory cytokines 
and endothelial activation markers, namely IL-6 and TNF-α , and intercellular adhesion molecule 1 (ICAM-1) 
and vascular cell adhesion molecule 1 (VCAM-1), respectively (Fig. 1B). Accordingly, when supernatants of cul-
tured cells were analyzed by ELISA, a time-dependent accumulation of the corresponding CCL2 and ICAM-1 
secreted proteins was also found (Fig. 1C,D).
Activation of NF-κ B is intrinsically involved in regulating the inflammatory response in the cardiovascular 
system22,23. Nuclear translocation of NF-κ B/p65 subunit is a key event in NF-κ B activation. An increased nuclear 
NF-κ B/p65 content in cells treated with CsA or tacrolimus for 30 min, which is compatible with the upregulated 
synthesis of proinflammatory factors previously found, was observed by confocal immunofluorescence (Fig. 2A). 
Indeed, pretreatment of cells with the NFκ B inhibitor parthenolide23, prevented the CNI-induced CCL2, CCL5, 
ICAM-1 and VCAM-1 expression (Fig. 2B). Taken together, these results are consistent with a role of NF-κ B 
regulating the CNI-induced proinflammatory events in endothelial cells.
Toll-like receptor signaling is a key event mediating CNI-induced proinflammatory activity in 
endothelial cells. The vasculature may react against injury by activating TLRs, which are key innate immunity 
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sensors that promote endothelial activation and inflammation. Since lack of the adaptor protein MyD88 precludes 
TLR-derived signaling leading to NF-κ B activation, we studied the role of TLRs in CNI-induced proinflammatory 
events by gene silencing of MyD88 expression in endothelial cells. Knockdown of MyD88 was successfully achieved 
in cells transfected with a specific MyD88-siRNA as judged by the very low protein expression compared to cells 
Figure 1. CNIs induce the expression of inflammatory mediators and endothelial activation markers in 
murine endothelial cells. The expression of proinflammatory cytokines and endothelial activation markers was 
evaluated in murine endothelial cells exposed to cyclosporine (CsA) or tacrolimus (Tac). (A) Dose-dependent 
CCL2 and CCL5 mRNA expression in cells treated for 6 h with 10–20 μ g/ml CsA or Tac, assessed by qRT-PCR. 
(B) TNF-α , IL-6, ICAM-1 and VCAM-1 mRNA expression in cells treated with 10 μ g/ml CsA and 20 μ g/ml 
Tac, qRT-PCR. (C,D) CCL2 (C) or ICAM-1 (D) protein levels assessed by ELISA in supernatants from cells 
stimulated with 10 μ g/ml CsA, 20 μ g/ml Tac or vehicle (Control). Data represent the mean ± SEM of three 
independent experiments. * p ≤ 0.05 vs control.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:27915 | DOI: 10.1038/srep27915
transfected with a scramble siRNA (Fig. 3A). In addition, functional assays showed that MyD88 silencing pre-
vented the CCL2 and ICAM-1 synthesis induced by LPS, a known agonist of the TLR/MyD88 pathway (Fig. 3B,C). 
Significantly, MyD88 knockdown also decreased CNI-induced CCL2 and ICAM-1 protein synthesis, as assessed by 
ELISA in culture supernatants (Fig. 3B,C). Moreover, taking tacrolimus as representative CNI, MyD88 deficiency 
resulted in the inhibition of key events leading to NF-κ B pathway activation, namely Iκ Bα and p65 phosphoryla-
tion (Fig. 3D). These results support the conclusion that engagement of TLR is an initial event that promotes NF-κ B 
activation and hence the synthesis of proinflammatory genes in endothelial cells exposed to CsA or tacrolimus.
TLR4 is a specific target of CNIs in endothelial cells. Based on results obtained in endothelial cells 
with silenced MyD88, we searched for specific TLRs that could mediate the proinflammatory effects of CNIs. We 
focused on TLR4 because of its inherent relevance in vascular disease24. Pharmacological inhibition of TLR4 with 
CLI-095, which specifically blocks signaling from the TLR4 intracellular domain, thoroughly repressed CsA- and 
tacrolimus-induced NF-κ B/p65 nuclear translocation (Fig. 4A) and gene expression of inflammatory cytokines 
Figure 2. Proinflammatory responses elicited by CNIs in endothelial cells depend on NF-κB activation. 
(A) Representative confocal microscopy immunofluorescence images showing NF-κ B/p65 (green) nuclear 
translocation in cells stimulated for 30 min with 10 μ g/ml CsA and 20 μ g/ml Tac. Nuclei were counterstained 
with or with 4′,6-diamino-2-fenilindol (DAPI) (blue). Original magnification x400. (B) Addition of the NF-κ 
B inhibitor parthenolide 1 h before stimuli, abolished the CsA or Tac-induced CCL2, CCL5, ICAM-1 and 
VCAM-1 mRNA upregulation at 6 h. Mean ± SEM of three independent experiments. * p ≤ 0.05 vs control; 
#p ≤ 0.05 vs CsA, †p ≤ 0.05 vs Tac.
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Figure 3. CNI-induced proinflammatory responses in endothelial cells depend on MyD88 signaling. (A) The 
overall efficiency of the transfection procedure was assessed by detection of MyD88 expression by western blot in 
total protein extracts from cells transfected with a scramble siRNA (sc-siRNA) or with a MyD88 siRNA (MyD88-
siRNA). After transfection, cells were stimulated with vehicle, CsA or Tac for 24 h. The figure is a representative 
experiment showing an almost undetectable expression of MyD88 in MyD88-siRNA transfected cells compared 
to expression levels in cells transfected with the sc-siRNA. CsA or Tac did not significantly change MyD88 
expression. β -actin was used as protein loading control. (B,C) Secretion of CCL2 and ICAM-1 was evaluated by 
ELISA in supernatants from control cells or from sc-siRNA or MyD88-siRNA transfected cells stimulated with 
CsA, Tac or vehicle for 24 h. Functional efficiency of MyD88 silencing was assessed in cells stimulated for 24 h with 
1 μ g/ml LPS, used as a control. Bar graphs represent the Mean ± SEM of a set of six independent experiments. 
(D) Activation of the MyD88-dependent NF-κ B pathway assessed by phosphorylated Iκ Bα (p-Iκ Bα ) and RelA/
p65 (p-p65) levels in total protein extracts from sc-siRNA or MyD88-siRNA MS1 transfected cells treated with 
20 μ g/ml Tac. Image shows representative western blots of p-Iκ Bα and p-p65 from sets of four independent 
experiments for each protein and the corresponding quantification bar graphs depict the mean ± SEM. A control 
western blot showing the lack of MyD88 expression in this experiment is also showed at the figure bottom. GAPDH 
was used as protein loading control. * p < 0.05 vs control (siRNA control); #p < 0.05 vs CsA or Tac (siRNA-MyD88).
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represented by CCL2, CCL5, TNF-α and IL-6 (Fig. 4B) and adhesion molecules, including VCAM-1, ICAM-1 
and SELE (Fig. 4C). These results indicate a key role of TLR4 promoting CNI-induce endothelial inflammation, 
since this response was almost completely inhibited by the receptor blockade.
The preceding results show that in endothelial cells, CNIs activate TLR4 to transduce input signals into 
MyD88-dependent proinflammatory effects. To study whether CNI also activate a MyD88-independent path-
way, we tested for phosphorylation of the transcription factor IRF3, which is activated following TLR4/TRIF 
Figure 4. Pharmacological inhibition of TLR4 blocked proinflammatory responses induced by CsA 
and tacrolimus in endothelial cells. Cells were incubated with 10 μ g/ml CsA or 20 μ g/ml Tac alone or in the 
presence of the TLR4 inhibitor, CLI095 (added 6 h before the CNIs). (A) Activation of NF-κ B was assessed 
through the nuclear translocation of the NF-κ B/p65 subunit detected by immunofluorescence confocal 
microscopy. Control cells show a cytoplasmic NF-κ B/p65 staining (green) whereas in cells stimulated with CsA 
or Tac, NF-κ B/p65 was mostly located inside nuclei. By contrast, the TLR4 inhibitor CLI-095 prevented nuclear 
translocation of NF-κ B/p65. Cells were also stimulated with TNF-α (30 ng/ml) alone as a positive control of 
NF-κ B activation or preincubated with CLI-095 to prove that TLR4 inhibition does not interfere with TNF-α 
-mediated NF-κ B/p65 translocation. (B,C) Transcriptional levels of proinflammatory cytokines (CCL2, CCL5, 
TNF-α , IL-6) (A) and endothelial activation markers (ICAM-1, VCAM1, SELE) (B) were evaluated by qRT-PCR. 
Data are mean ± SEM of three independent experiments. * p ≤ 0.05 vs control; #p ≤ 0.05 and †p ≤ 0.05 vs CsA or 
Tac, respectively.
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engagement, in endothelial cells exposed to CsA or tacrolimus. Immunoblot assays disclosed a rapid increase of 
IRF3 phosphorylation from 15 minutes after addition of CsA or tacrolimus (Fig. 5A). Moreover, CsA and tac-
rolimus also activated the transcription of the IRF3 target INFβ 1, and also of the INFβ 1-regulated proteins IRF1 
and IRF7 (Fig. 5B). Thus, these results support the hypothesis that CNIs also trigger the MyD88-independent 
pathway by recruiting IRF3 at proximal TRIF-adapted TLR4 signaling complexes. Finally, we studied whether 
TRIF-dependent signaling influenced MyD88-dependent responses. To this end, before incubation with CNIs, 
endothelial cells were treated with Resveratrol to inhibit the assembly of TBK1 and RIP1 kinases in TLR4-TRIF 
complexes and hence avoid IRF3 activation25. Resveratrol significantly reduced CCL2 gene expression, thus sup-
porting that the TRIF-dependent TLR4 pathway also contributes to the overall CNI-dependent proinflammatory 
response triggered by TLR4 engagement in endothelial cells (Fig. 5C).
Calcineurin knockdown partially inhibits the activation of TLR4-dependent pathway elicited 
by CNIs in endothelial cells. The role of calcineurin in CNI-induced proinflammatory endothelial events 
was specifically addressed by gene silencing of the α isoform of the catalytic subunit, thus preventing calcineu-
rin activation and calcineurin stabilization by impeding the interaction of CNI-cyclophilin complexes with the 
regulatory calcineurin B subunit26,27. In comparison with control cells transfected with the scramble siRNA, cal-
cineurin expression was significantly reduced in endothelial cells transfected with a specific calcineurin siRNA 
(Fig. 6A). Calcineurin knockdown did not modify CCL2 and ICAM1 secretion by itself but partially inhibited the 
CNI-induced CCL2 and ICAM1 secretion into the cell culture media (Fig. 6B). To test whether TLR4 signaling 
modulation by calcineurin is a general mechanism, we stimulated the cells with the specific TLR4 ligand LPS. 
Accordingly, a quantitatively similar inhibition of CCL2 and ICAM1 production was observed in LPS-treated 
calcineurin silenced endothelial cells (Fig. 6B). Consistent with the partial reduction of CNI-induced CCL2 and 
ICAM1 secretion, calcineurin silencing barely downregulated Iκ Bα activation and furthermore, it did not modify 
p65 phosphorylation, an important event to enhance inflammatory gene transcription, in response to tacrolimus as 
representative CNI (Fig. 6C). However, activation of the TRIF-dependent pathway induced by CsA and tacrolimus, 
assessed by detection of phosphorylated IRF3 by western blot, was completely prevented by calcineurin deficiency 
(Fig. 6D). Overall, these results show that calcineurin absence can downregulate, at least in part, TLR4-derived 
proinflammatory signals evoked by the CNIs. Thus, normal calcineurin expression could heighten this response.
CNIs induce proinflammatory cytokine production and endothelial activation in isolated mice 
aortas and VSMCs. CNIs alter vascular homeostasis by causing endothelial dysfunction, increased extracel-
lular matrix deposition and hypertension. Subtle endothelial inflammation may contribute to these vascular wall 
pathogenic processes; however, a proinflammatory effect of CNIs on vascular tissue has not yet been explored. 
In ex vivo aorta cultures, CsA activated NF-κ B as indicated by the increased expression and nuclear transloca-
tion of the NF-κ B/p65 subunit in both endothelial cells (Fig. 7A) and VSMC (Fig. 7B). Similar behavior of p65 
was also observed when aortas were treated with tacrolimus (data not shown). Likewise, CsA and tacrolimus 
also increased mRNA levels encoding NF-κ B-regulated proinflammatory cytokines involved in vascular injury, 
including CCL2, CCL5, IL-6 and TNF-α (Fig. 7C). Moreover, CsA and tacrolimus also increased the mRNA 
expression of the endothelial activation marker ICAM-1 and the vascular dysfunction marker endothelin-1 
(ET-1) (Fig. 7D). To explore whether CNI-induced proinflammatory effects on vascular tissue require TLR4 
activation, a pharmacological approach was used. Pretreatment of mice aortas with CLI-095 significantly pre-
vented both NF-κ B activation (Fig. 7A,B) and hence the increased proinflammatory gene expression promoted 
by the CNIs (Fig. 7C,D). Interestingly, pharmacological TLR4 inhibition also prevented CNI upregulation of 
ET-1 mRNA expression, a key factor involved in the endothelial dysfunction (Fig. 7D). To reinforce these results, 
studies were done in aortas from TLR4−/− mice. CsA or tacrolimus stimulation did not upregulate CCL2, IL6, 
ICAM-1 or ET-1 gene expression in isolated aortas from TLR4−/− mice, thus confirming that TLR4 is a key 
intermediary of pathological vascular responses to CNI. Importantly, TLR4 deficient aortas were still responding 
to the inflammatory cytokine TNF-α , a not TLR4 ligand, as revealed by the increased CCL2, IL-6, ICAM-1 and 
ET-1 mRNA levels (Fig. 7E).
VSMCs play a central role in vascular inflammation and injury and may be a CNI target. Thus, we explored 
whether VSMCs contribute to the CNI-induced aortic inflammation. As in the case of endothelial cells and aorta, 
VSMCs increased CCL2, IL-6 and TNF-α mRNA levels in response to CNIs and this was prevented by TLR4 
inhibition (Fig. 7F). This result suggests that activation of the TLR4 pathway by CNIs is highly conserved in the 
most relevant cell types of the vascular wall.
CNI-produced inflammation is linked to TLR4-dependent ROS production. Oxidative stress is a 
key mediator of inflammation in vascular disease so we explored whether CNIs increased reactive oxygen species 
(ROS) production in ex vivo cultured aortas exposed to CNIs alone or following exposure to CLI-095. Compared 
to untreated control aortas, those exposed to CsA showed an increased O2−/ROS production, mainly located to 
VSMCs but also detectable in endothelial cells (Fig. 8A). By contrast, pre-treatment with CLI-095 before CsA 
addition prevented ROS production as assessed by DHE staining, proving that TLR4 activation regulates O2−/ROS 
production (Fig. 8A). Similar results were obtained when aortas were incubated with tacrolimus (data not shown).
The precise contribution of TLR4-dependent O2−/ROS increases to CNI-induced vascular inflammation 
was further evaluated in endothelial cells chosen as model of CNI-induced TLR4 signaling. Similar to aorta 
experiments, pharmacological TLR4 inhibition also repressed O2−/ROS production as assessed by DHE stain-
ing (Fig. 8B). Further, the NADPH inhibitors apocinin and DPI prevented the the upregulated CCL2, CCL5, 
VCAM-1 and ICAM-1 mRNA expression induced by CsA and tacrolimus (Fig. 8C). Altogether, these results 
point to oxidative stress and O2−/ROS production as a contributor to CNI-induced vascular inflammation and 
localized O2−/ROS formation downstream of TLR4 activation.
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Figure 5. CsA and tacrolimus activate the TLR4/TRIF-dependent signaling pathway in endothelial cells. Cells 
were treated with CsA or Tac as in the preceding figures. (A) Representative western blots of the phosphorylated 
IRF3 (p-IRF3) using total protein extracts from cells treated with CsA or Tac for 15 to 60 min. Bar graphs represent 
the mean ± SEM from three independent experiments. * p ≤ 0.05 vs control. (B) Activity of the TRIF pathway was 
assessed by qRT-PCR quantification of IRF3 target gene (INFβ 1, IRF7, IRF1) mRNA in cells stimulated with CsA or 
Tac for 6 h . Data expressed as mean ± SEM of fold-change over control of at least three independent experiments. 
* p ≤ 0.05 vs control. (C) TRIF pathway and proinflammatory response. Cells were stimulated with CsA or Tac for 
6 h following pretreatment with 50 μ M resveratrol. CCL2 mRNA expression was assessed by qRT-PCR. Bar graph 
represents mean ± SEM from three independent experiments. * p ≤ 0.05 vs control; #p ≤ 0.05 vs CsA, †p ≤ 0.05 vs Tac.
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Figure 6. CNI proinflammatory activity in endothelial cells is partially dependent on calcineurin. Cells 
were transfected with a control scrambled siRNA (sc-RNA) of with a specific calcineurin siRNA (CaN-siRNA) 
and then stimulated with CsA or Tac to assess the efficiency of the silencing procedure (A), the magnitude of the 
overall proinflammatory response (B) or the activation of NF-κ B signaling (C). (A) Representative western blot 
showing calcineurin expression in control sc-siRNA or in CaN-siRNA cells stimulated with vehicle, CsA or Tac 
for 24 h. β -actin was used as protein loading control. (B) CCL2 and ICAM-1 ELISA in supernatants of sc-siRNA 
or CaN-siRNA transfected cells stimulated with CsA or Tac for 24 h. As positive control for TLR4 signaling cells 
were also stimulated with 1 μ g/ml LPS. Quantification graphs represent the mean ± SEM of six independent 
experiments. * p < 0.05 vs sc-siRNA; #p < 0.05 vs Calcineurin-siRNA. (C) Comparative levels of calcineurin, 
phosphorylated Iκ Bα (p-Iκ Bα ) and NF-κ B/p65 (p-p65) in control, sc-siRNA or in CaN-siRNA transfected cells 
stimulated with Tac for 24 h. Image shows representative western blots from three independent experiments 
and the corresponding quantification bar graph. * p < 0.05 vs control (siRNA control); #p < 0.05 vs CsA or Tac 
(siRNA-Calcineurin). GAPDH was used as protein loading control.
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Figure 7. CNI induce inflammation in wild-type aortas but not in aortas from TLR4−/− mice. Aorta tissue 
segments extracted from wild-type or TLR4−/− C57BL/6 mice were stimulated for 6 h with 10 μ g/ml CsA 
or 20 μ g/ml Tac. CLI-095 was added 6 h before stimulation with the CNIs. (A,B) Confocal microphotographs 
showing NF-κ B/p65 content and location in control or CsA or CsA plus CLI-095 treated aortic sections from wild-
type mice. Activation of NF-κ B/p65 was detected by intensification of the specific red fluorescence in cytoplasm 
and nucleus of either endothelial cells recognized by CD31 staining (green fluorescence surrounding the cell 
borders) (A) or VSMC cells expressing α SMA (cytoplasmic green fluorescence) (B). Endothelial cells were found 
lining the intima layer and facing the lumen and VSMC located in the media layer. Yellow asterisks point cells with 
nuclear translocation of p65 and white asterisks indicate cells with increased cytoplasmic p65 expression. White 
arrows point endothelial and VSMC without increased expression of p65 in control or CLI095 treated aortas. 
White arrowheads in A show elastin fibers (green autofluorescence) which otherwise are not apparently visualized 
in B because the much higher α SMA specific fluorescence. Nuclei were counterstained with DAPI. Original 
magnification x630. (C,D) Gene expression of CCL2, CCL5, IL-6, TNF-α (left panel) and ICAM-1, ET-1(right 
panel) in cultured aorta sections from wild-type mice exposed to CsA or Tac alone or in the presence of CLI-095. 
Data are expressed as mean ± SEM of 4 samples. * p < 0.05 versus control non-stimulated aortas; #p < 0.05 vs 
CsA or Tac treated aortas. (E) Gene expression of CCL2, IL-6, ICAM-1 and ET-1 in cultured aorta sections from 
TLR4−/− mice exposed to CsA, Tac or TNF-α . Data are the mean ± SEM of 4 samples. * p < 0.05 versus control 
non-stimulated aortas. (F) CCL2, IL-6 and TNF-α mRNA expression in VSMC stimulated for 6 h with 10 μ g/ml 
CsA or 20 μ g/ml Tac alone or pretreated with vehicle or CLI-095. Data represent the mean ± SEM of at least three 
independent experiments. * p ≤ 0.05 vs control; #p ≤ 0.05 and †p ≤ 0.05 vs CsA or Tac alone, respectively.
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Figure 8. Activation of the TLR4 pathway by CsA and tacrolimus increases the production of O2−/ROS 
as inflammation mediator in aorta and endothelial cells. (A) Confocal photomicrographs of aortic tissue 
sections treated with 10 μ g/ml CsA for 6 h showing an increased O2−/ROS production measured as DHE 
staining (red fluorescence). Elastin auotofluorescence (green) shows the structure of the artery that contrast 
with the red fluourescence indicating that O2−/ROS was mainly located in VSMCs (media layer) and also in 
endothelial cells (intima layer). White arrowhead shows DHE positive VSMCs and asterisk point DHE positive 
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Discussion
We have shown that CNIs modulate vascular behaviour by inducing proinflammatory events, namely endothelial 
activation as well as production of inflammatory cytokines, through TLR4 activation and ROS generation in 
endothelial cells and VSMC as well as in aortic tissue.
The role of the innate immunity and associated inflammatory mechanisms in the development of the vascular 
adverse effects of CNIs had not been specifically addressed previously. Vascular inflammation is a central process 
underlying endothelial dysfunction, vascular damage and progression of cardiovascular disease28,29. Recent stud-
ies from our group disclosed that CNIs promote tubular inflammation in kidneys10. The present research demon-
strated that CNIs also have proinflammatory effects on endothelial cells and VSMC, thus widening the spectrum 
of cell types susceptible to the inflammatory action of CNIs. A prior report explored the modulation by CsA 
of TNF-α /LPS-induced endothelial cell inflammation and observed that CsA promoted inflammation-induced 
monocyte adhesion to human intestinal endothelial cells but paradoxically, reduced inflammation-induced iNOS 
activation and adhesion molecule expression30. Our results demonstrating that CNIs by themselves increased the 
expression of a complete spectrum of endothelial activation markers and inflammation mediators in cultured 
endothelial cells and murine aortas in a TLR4-dependent manner provide a better understanding of CNI-induced 
vascular injury and provide a knowledge frame to explain prior observations. Thus, direct induction of endothe-
lial activation and cytokine production by CNIs may contribute to allograft vascular injury as well as to 
nephrotoxicity. While endothelial injury and inflammation negatively impact on normal VSMCs function, an 
inflammatory response from VSMC may also contribute to endothelial injury and dysfunction. Results obtained 
in isolated aortas and cultured VSMC point to a potential role of aorta-generated inflammatory cytokine, such as 
IL-6 and TNF-α , secreted in response to CNIs, in an autocrine or paracrine loop resulting in additional endothe-
lial activation, cytokine production and worsening of the systemic vascular function13,29.
NF-κ B is the major mediator of the inflammatory response in vascular cells and other cell types, and as such, it 
is an attractive target for chemoprevention of inflammatory diseases22,31. NF-κ B expression correlates with upreg-
ulation of chemokines in human cardiovascular disease and in experimental models of vascular damage22,28,32–34. 
We previously demonstrated that CNIs activate NF-κ B in renal tubular cells in vitro and in a mouse model of CsA 
nephrotoxicity10. In the present work, by means of pharmacological inhibition of Iκ B kinase and Iκ Bα stabili-
zation with parthenolide, we showed that NF-κ B mediates the CNI-induced synthesis of key proinflammatory 
cytokines and adhesion molecules in endothelium. Moreover, CNIs activated NF-κ B in the entire vascular wall, 
including VSMC. This is relevant for CNI toxicity since NF-κ B inhibition with parthenolide prevents experimen-
tal atherosclerosis and renal damage33,35,36. Thus, synthetic or naturally occurring NF-κ B small molecule inhibi-
tors should be explored to prevent CNI-induced vascular inflammation.
Increased activity or expression of TLRs, particularly TLR4, has been associated with vascular inflamma-
tion19,37,38. In accordance with previous observations from our group on CNI-induced TLR activation in tubular 
cells, MyD88 silencing in endothelial cells prevented the induction of proinflammatory and endothelial activation 
markers by CsA and tacrolimus. MyD88 is an adaptor protein that participates in the formation of proximal com-
plexes with TLR2 and TLR412,39. However, in our experiments, cultured endothelial cells did not respond to the 
TLR2 agonist lipoteichoic acid (data not shown). This allowed focusing research on the role of the TLR4 pathway 
in the proinflammatory effects of CNIs. Both pharmacological and genetic targeting of TLR4 confirmed its role in 
CNI-induced inflammatory responses in endothelial and vascular cells. Remarkably, TLR4 was also required for 
CNI-induced ET-1 gene expression. ET-1 is a potent vasoconstrictor peptide involved in hypertension40. This result 
reinforces the idea of endothelial inflammation, activation and dysfunction being related phenomena in response 
to CNIs and disclosed a central role of TLR4 as a gatekeeper controlling all of these responses in vascular cells.
We also identified oxidative stress as a key event downstream of TLR4 in aortic endothelial and vascular cells 
exposed to CNIs. Oxidative stress contributed to the CNI-induced synthesis of proinflammatory mediators and 
endothelial stress markers. A pathway implying a TLR4-dependent ROS formation, NF-κ B activation and inflam-
mation was reported in VSMCs subjected to AngII treatment18,23. CsA is a well-known inducer of oxidative stress 
and cell damage in the vasculature, and notably, in renal tissue41,42 Likewise, previous work from our laboratory 
showed that ROS mediate CsA-induced cell death in endothelial cells through activation of the JAK2/STAT3 
pathway43. Moreover, it is well known that JNK is activated by oxidative stress44. In endothelial MS1 cells, both 
JAK2 and JNK are activated by CNIs and their inhibition results in the blockade of the CNI-provoked proinflam-
matory responses (data not shown). Downstream transcription factors of these protein kinases, namely STAT3 
and AP-1, an even their activating protein kinases, interact with NF-κ B to activate inflammatory responses45–47. 
Thus, our present results strongly suggest a role of redox imbalance and ROS generation in the TLR4-dependent 
signaling and NF-κ B-dependent inflammation.
The observation that vascular and kidney toxicity profiles of CsA and tacrolimus are similar in experimental 
models and humans, suggests that their interaction with calcineurin could be a common element involved in 
endothelial cells, which are showed at a larger augment (inset). Aortas subjected to pharmacological TLR4 
inhibition with CLI-095 show a lesser DHE staining. Original magnification x630. (B) Representative confocal 
photomicrographs of O2−/ROS production measured as DHE positive staining in murine endothelial MS1 cells 
treated with 10 μ g/ml CsA (A) or 20 μ g/ml Tac for 6 h. Cells subjected to pretreatment with CLI-095 before 
CsA or Tac stimulation exhibit a basal DHE staining after treatment with CsA or Tac. (D) Gene expression of 
proinflammatory factors and adhesion molecules (CCL2, CCL5, VCAM-1 and ICAM-1) was assessed by PCR 
in MS1 cells treated with 10 μ g/ml CsA (A) or 20 μ g/ml Tac for 6 h, both in the presence or in the absence of the 
NADPH inhibitors Apocinin (10 mM) and DPI (10 μ M) added 1 h before the stimuli. The bar chart represent 
the Media ± SEM of a set of three independent experiments. * p ≤ 0.05 vs control; #p ≤ 0.05 and †p ≤ 0.05 vs CsA 
or Tac alone, respectively.
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the CNIs adverse effects. In endothelial cells, the interaction of CNIs with calcineurin is required for decreasing 
eNOS activity and NO content. However, calcineurin was dispensable to increase TGFβ receptor expression and 
arteriolar hyalinosis or to potentiate the LPS-induced leukocyte binding to endothelium, as suggested by similar 
results obtained with rapamycin9,30,48. In macrophages, unlike in T cells, calcineurin hindered NF-κ B and IRF 
activation by inhibiting TLR-mediated signaling through MyD88 and TRIF, and calcineurin targeting by genetic 
means or by CNIs resulted in increased synthesis of proinflammatory cytokines49. In the present manuscript, 
unlike in macrophages, calcineurin deficiency did not increase proinflammatory factor secretion. By contrast, 
it partially inhibited but did not impede the overall CNI-induced proinflammatory response, suggesting that 
binding of CNIs to calcineurin may enhance the proinflammatory effect, but is not an absolute requirement. In 
accordance with this result, calcineurin deficiency mildly reduced evidence of NF-κ B activation at the Iκ Bα phos-
phorylation level, but this fact did not result in modification of p65 phosphorylation/activation. This observation 
is in agreement with the reported phosphorylation of p65 at Ser536 being independent of Iκ Bα 50. Moreover, 
according to the proposed role of Ser536 p65 phosphorylation promoting inflammatory gene expression51, main-
tenance of Ser536 p65 phosphorylation was associated to a largely preserved inflammatory gene expression fol-
lowing CNI exposure. By contrast, our results revealed that calcineurin deficiency abolished the CNI-induced 
TRIF signaling. The TRIF pathway promotes sustained NF-κ B-dependent responses following TLR4/MyD88 
signaling52. In this manner, we could envisioned a role of calcineurin suppressing long lasting activation of TLR4 
and the loss of this inhibitory feedback as a possible mechanism contributing to exacerbation of CNI toxicity. 
Overall, this set of results show that calcineurin availability is not an absolute requirement, but it may contribute 
to CNI-induced proinflammatory events in endothelial cells. Thus, interaction with calcineurin could stabilize 
CNIs inside cells and increase toxicity.
In conclusion, we have shown that TLR4 mediates endothelial inflammation, activation and dysfunction 
induced by CNIs. These effects appear to be dependent on the TLR4/MyD88/NF-κ B and TLR4/TRIF/NF-κ B path-
ways and involved oxidative stress generation downstream of TLR4 and upstream of NF-κ B activation. Although 
calcineurin expression appeared to heighten CNI-mediated TLR4 signaling and hence NF-κ B-dependent 
cytokine and adhesion protein synthesis to some extent, this final proinflammatory effect was largely observed 
even in calcineurin-deficient cells. By contrast, results showed that TLR4 is an essential mediator of CNI proin-
flammatory effects in the vasculature. The association between TLR4 inactivation and improving of cardiovascu-
lar disease is becoming increasingly clear from a range of animal models dealing with this topic17,18,53,54. Indeed, 
TLR4 blockade arises as potential therapy against many manifestations of transplant and CNI-associated vascular 
disease, including inflammation, hypertension and atherosclerosis. CNI immunosuppression is presently una-
voidable to overcome allograft rejection, although prevention of CNI toxic side effects, including vascular toxicity, 
is yet an unmet necessity. Adjuvant therapies could be an acceptable strategy to improve immunosuppression 
based on CNIs. In such a way, TLR4 inhibition could be envisioned as a potential therapeutic approach for pre-
vention of CNI-associated vascular toxicity after transplant.
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